Nat Commun:日研究找到易被特定癌细胞吸收的肽

2012-07-23 新华网 新华网

新一期英国在线科学期刊《自然—通讯》(Nature Communications)发表了日本的一个研究小组的研究报告,他们发现了大肠癌、乳腺癌、白血病(俗称“血癌”)等10种癌细胞容易吸收的肽,这将有助于这些癌症的早期发现与治疗。 综合日本媒体报道,日本爱知县癌症中心研究所、琉球大学等机构的研究人员以溶液中氨基酸排列方式不同的1万亿种肽为对象,研究各种癌细胞对它们吸收的难易程度,结果发现白血病细

新一期英国在线科学期刊《自然—通讯》(Nature Communications)发表了日本的一个研究小组的研究报告,他们发现了大肠癌、乳腺癌、白血病(俗称“血癌”)等10种癌细胞容易吸收的肽,这将有助于这些癌症的早期发现与治疗。

综合日本媒体报道,日本爱知县癌症中心研究所、琉球大学等机构的研究人员以溶液中氨基酸排列方式不同的1万亿种肽为对象,研究各种癌细胞对它们吸收的难易程度,结果发现白血病细胞容易吸收肽CPP44。

研究人员让能够抑制癌细胞增殖的抗癌物质与CPP44结合,以治疗患白血病的实验鼠。结果,实验鼠体内的癌细胞得以更充分地吸收抗癌物质,癌组织缩小到原先的50%至30%,实验鼠生存时间有所延长。同时,这种治疗未引发明显的副作用。

通过这项研究,科研人员找到了大肠癌、乳腺癌、肺癌等10种癌细胞容易吸收的特定种类的肽。参与研究的肿瘤病理学专家近藤英作介绍说,此前研究者发现易被癌细胞吸收的肽同时也易被正常细胞吸收,找到只容易被癌细胞吸收的肽十分不易。

研究人员指出,利用这些肽承担抗癌药物“搬运工”,能使药物被集中送达癌细胞,有助于抑制副作用。另外,即使肿瘤体积还很小,如果让这些肽与色素相结合并注入肌体,就能使肿瘤组织变色且便于观察,从而帮助尽早发现癌症。

doi:10.1038/ncomms1952
PMC:

PMID:

Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems

Eisaku Kondo,1, 2 Ken Saito,1 Yuichi Tashiro,3 Kaeko Kamide,4 Shusei Uno,4 Tomoko Furuya,5 Masao Mashita,6 Kiichiro Nakajima,7 Tomoyuki Tsumuraya,8 Naoya Kobayashi,9 Masahiro Nishibori,10 Mitsune Tanimoto11 & Masayuki Matsushita8

Cell-penetrating peptides have gained attention owing to their promise in noninvasive delivery systems. Among the identified cell-penetrating peptides, the TAT peptide has been preferentially used for transduction into cells of diverse origins. However, this activity is nonselective between neoplastic and non-neoplastic cells. Here we describe artificial cell-penetrating peptides that are selectively and efficiently incorporated into human tumour cells, according to their lineage. Ten representative tumour lineage-homing cell-penetrating peptides were obtained by screening of a random peptide library constructed using messenger RNA display technology, and some of the isolates were further modified by amino-acid substitution. Their advantageous tumour cell-targeting ability is corroborated in an in vivo mouse model for imaging and growth suppression of metastatic xenoplant tumours. These cell-penetrating peptides are potentially useful for the efficient targeting of human neoplasms in a tumour origin-dependent manner, and provide a framework for the development of peptide-based anti-tumour technologies.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086617, encodeId=4ab1208661e9b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 22 07:57:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879320, encodeId=d23f18e93202a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 27 11:57:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804982, encodeId=89ae18049823f, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 29 12:57:00 CST 2012, time=2012-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251902, encodeId=07861251902c7, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 25 04:57:00 CST 2012, time=2012-07-25, status=1, ipAttribution=)]
    2013-03-22 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086617, encodeId=4ab1208661e9b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 22 07:57:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879320, encodeId=d23f18e93202a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 27 11:57:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804982, encodeId=89ae18049823f, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 29 12:57:00 CST 2012, time=2012-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251902, encodeId=07861251902c7, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 25 04:57:00 CST 2012, time=2012-07-25, status=1, ipAttribution=)]
    2013-03-27 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086617, encodeId=4ab1208661e9b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 22 07:57:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879320, encodeId=d23f18e93202a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 27 11:57:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804982, encodeId=89ae18049823f, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 29 12:57:00 CST 2012, time=2012-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251902, encodeId=07861251902c7, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 25 04:57:00 CST 2012, time=2012-07-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086617, encodeId=4ab1208661e9b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 22 07:57:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879320, encodeId=d23f18e93202a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 27 11:57:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804982, encodeId=89ae18049823f, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 29 12:57:00 CST 2012, time=2012-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251902, encodeId=07861251902c7, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 25 04:57:00 CST 2012, time=2012-07-25, status=1, ipAttribution=)]
    2012-07-25 yxch36

相关资讯

PLoS ONE:日本开发胰腺癌细胞吸收化疗药物的新疗法

  日前,日本札幌医科大学教授加藤淳二率领的研究小组在新一期美国《公共科学图书馆—综合》(PLoS ONE)上报告说,他们开发出一种治疗胰腺癌的新疗法,即利用癌细胞能吸收海藻糖的性质,在化疗过程中使癌细胞直接“吃药”,从而能够减少药量,并减小化疗药物对健康细胞的影响。 研究小组发现,胰腺癌细胞具有活跃吸收海藻糖的性质,于是将海藻糖与内部包有化疗药物的称为脂质体的薄膜结合在一起,然后注

新版日本《胃癌处理规约》解读

  日本从1962年开始制定和出版了第1版《胃癌临床和病理处理规约》,经过多次修订,到目前已出版了第14版《胃癌处理规约》。可以说,《胃癌处理规约》[以下简称《规约》]反映了日本胃癌诊疗发展的历史,是日本各个时期胃癌诊治的“金标准”。第13版和第14版《胃癌处理规约》的出版时间间隔10年,在这10年间,胃癌的病理学和临床研究均有了显著的进步。2001年3月,日本制定了《胃癌治疗指南》 [以下简称《